Ryan Fischer on PDUFA

Parent Project Muscular Dystrophy has long held the belief that new approaches are required to expedite the development of treatments for rare diseases like Duchenne. Patient advocates have worked tirelessly with Congress, over time through legislation, to increase the engagement of the patient voice within the regulatory review process for therapeutics.  Passed in 2012, The Food and Drug Administration Safety and Innovation Act (FDASIA) was a culmination of those advocacy efforts by patients.

Sharon Terry on PDUFA

This is not rocket science!  Running a molecule through all of the traps is really hard.  Understanding what people feel and think and experience with regard to the drugs they take and those they need is simple.  In most other areas of our lives, various industries know quite well what features we want on our smartphones, that we suddenly all want Greek yogurt, and that we don’t want to pay to use the bathroom on a plane.  In medicine, we have not yet realized the same dynamic and robust methods, tools and studies for understanding the needs and values of the end user.  The needs, wants, va

Sharon Terry

Ryan Fischer

Sascha on PDUFA

As important stakeholders in the drug development and approval process, patients provide a unique and valuable perspective when considering the benefits and risks of potential new and innovative medicines.  Patients can identify areas of unmet medical need, provide critical perspective on the impact of a disease and its manifestations, and uniquely inform the development of outcome measures that are meaningful to patients.  A scientific approach to gathering patient input is necessary to realize the shared goal of a patient-centered approach to drug development and regulatory review.  PhRMA

Sascha Haverfield

Select a Contributor Response


How can we best advance the science of patient input to improve the efficiency of the drug development and regulatory review process?

View All Conversations


How can we best advance the science of patient input to improve the efficiency of the drug development and regulatory review process?

Test Name
Test Title, Test Company

Read biography×
This is a test modal

Robert Metcalf on PFDD

Submitted by Emily on

The most recent reauthorization of the Prescription Drug User Fee Act (PDUFA) included new efforts by the Food and Drug Administration (FDA) to enable patients and patient groups to become actively involved in FDA evaluations of new medicines. Two programs in particular--the Patient-Focused Drug Development (PFDD) Initiative and Benefit/Risk Assessment--work in tandem to inform the FDA's decisions on whether or not to approve a medicine for patient use.

Peter L. Saltonstall on PDUFA

Submitted by Emily on

We at NORD believe that patients need to play a central and much more active role in the drug development process, from start to approval. Until very recently, the process has largely ignored the patient as an active participant.

Peter L. Saltonstall


Subscribe to PhRMA RSS